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Myeloablative therapy and autologous stem cell transplantation (ASCT) are underutilized in older patients with
B cell non-Hodgkin (B-NHL) lymphoma.Wehypothesized thatmyeloablative doses of 131I-tositumomab could be
augmented by concurrent ﬂudarabine, based on preclinical data indicating synergy. Patients were  60 years of
age and had high-risk, relapsed, or refractory B-NHL. Therapeutic infusions of 131I-tositumomab were derived
from individualized organ-speciﬁc absorbed dose estimates delivering  27 Gy to critical organs. Fludarabine
was initiated 72 hours later followed by ASCT to deﬁne the maximally tolerated dose. Thirty-six patients with a
median age of 65 years (range, 60 to 76), 2 (range, 1 to 9) prior regimens, and 33% with chemoresistant disease
were treated on this trial. Dose-limiting organs included lung (30), kidney (4), and liver (2) with a median
administered 131I activity of 471mCi (range, 260 to 1620). Fludarabinewas safely escalated to 30mg/m2 7 days.
Engraftment was prompt, there were no early treatment-related deaths, and 2 patients had  grade 4 non-
hematologic toxicities. The estimated 3-year overall survival, progression-free survival, andnonrelapsemortality
were 54%, 53%, and 7%, respectively (median follow up of 3.9 years). Fludarabine up to 210 mg/m2 can be safely
delivered with myeloablative 131I-tositumomab and ASCT in older adults with B-NHL.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION study demonstrated that the use of high-dose 131I-tositu-
Adults age 60 years and older make up the majority of the
approximately 70,000 individuals newly diagnosed with
non-Hodgkin lymphoma (NHL) each year in the United States
[1]. Despite improved initial therapies, this group of patients
is less likely to experience prolonged remissions and survival
compared with younger adults [2,3]. Though data suggest
that high-dose therapy and autologous hematopoietic stem
cell transplantation (ASCT) can improve outcomes for a va-
riety of NHL histologies, clinical data indicate that this
approach is much less often employed in older adults, pri-
marily based on studies suggesting an increased risk of
toxicity and treatment-related mortality [4].
Radioimmunotherapy (RIT) given in myeloablative doses
has been shown by our group and others to provide effective,
tolerable therapy for patients with relapsed B cell NHL (B-
NHL) [5-8]. Based on these observations, we previously
explored the use of myeloablative doses of single-agent 131I-
tositumomab and ASCT in adults age  60 years [9]. Thist at the 53rd annual meeting of the
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hematologic toxicity and long-term clinical beneﬁt in a
substantial subset of patients. However, as with other
transplantation modalities, relapse remained the primary
cause of failure.
Efforts to improve on the outcome of high-dose RIT-based
ASCT have primarily focused on the addition of agents
traditionally paired with total body irradiation, such as eto-
poside and cyclophosphamide, with these drugs given after
the majority of the radionuclide has decayed or been cleared
from the body [6,8]. In contrast, preclinical data suggest that
the purine analogs, such as cytarabine and ﬂudarabine,
optimally synergize with RIT when given concurrently with
radiation exposure to target sites [10,11]. This synergy is
thought to be related to the potentially lethal incorporation
of nonphysiologic nucleosides during the repair of the RIT-
induced single-strand DNA breaks [12].
Based on these preclinical data, we hypothesized that a
prolonged administration of therapeutic doses of ﬂudarabine
could be delivered concurrently with myeloablative doses of
131I-tositumomab with the potential to safely improve out-
comes in this high-risk group of older patients. We now
present the results from a phase I trial combining the
maximally tolerated dose (MTD) of single agent 131I-tositu-
momab (27 Gy) with escalating doses and prolonged dura-
tion of administration of ﬂudarabine. These data representTransplantation.
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demonstrate the feasibility of administration of chemo-
therapy to patients who are receiving high-energy gamma
and beta irradiation, and show that up to 210 mg/m2 of ﬂu-
darabine can be safely added as part of an ASCT preparative
regimen.Figure 1. Treatment schema. Note that 3 patients received 1.7 mg/kg 131I-
tositumomab.PATIENTS AND METHODS
Patients
Patients with relapsed or refractory B-NHL or mantle cell lymphoma
(MCL) in ﬁrst remission were required to be  60 years of age at the time of
enrollment. Patients were required to have tumors expressing CD20, serum
creatinine <2.0 mg/dL, serum bilirubin <1.5 mg/dL, expected survival of
>60 days, Eastern Cooperative Oncology Group performance status of <2,
the ability to perform self care in radiation isolation, and  2  106 autol-
ogous CD34 cells/kg cryopreserved. Patients were excluded if they had
active systemic infection, active central nervous system lymphoma, abnor-
mally decreased cardiac ejection fraction, diffusion capacity of carbon
monoxide of <50% predicted, or had received >20 Gy of radiotherapy to a
critical normal organ (lung, liver, kidneys, spinal cord,>25% of red marrow).
Documentation of <.1% tumor contamination of the peripheral blood at the
time of stem cell harvest or the collected product was also required. The
institutional review board of the Fred Hutchinson Cancer Research Center
approved this protocol and all patients provided written informed consent.
The protocol was registered at ClinicalTrials.gov (NCT00110071).Biodistribution Studies
Thyroid uptake of 131I was blocked with oral potassium iodide, which
was initiated 24 hours before RIT and continued for 30 days after the ther-
apeutic infusion. All patients were premedicated with acetaminophen and
diphenhydramine and then underwent outpatient biodistribution studies
for dosimetry using tositumomab (1.7 mg/kg as a single infusion, n ¼ 3 or
485 mg ﬂat dose, n ¼ 33) labeled with 185 to 370 megabequerel (5 to
10 mCi) of 131I, followed by serial quantitative planar gamma camera im-
aging to calculate individualized organ-speciﬁc absorbed dose estimates
(cGy/megabequerel), based on CT-derived organ volumes as previously
published [5,13,14]. Absorbed dose estimates were obtained by integrating
the time-activity curves and applying the calculation methods recom-
mended by the Medical Internal Radiation Dose Committee of the Society of
Nuclear Medicine (Reston, VA). The overall treatment schema is shown in
Figure 1.Therapeutic Antibody Infusions
After completion of biodistribution studies, patients were admitted to
lead-lined radiation isolation rooms for therapeutic infusions. Patients were
premedicated with ondansetron, acetaminophen, and diphenhydramine
and hydrated with 5% dextrose in .45% sodium chloride at 200 mL/hour
intravenously, starting 1 hour before therapy and continuing 48 hours after
131I-tositumomab therapy. Therapeutic infusions were given with the
identical protein dose (1.7 mg/mg in-house labeled or 485 mg ﬂat dose from
commercially labeled product) and infusion schedule as in dosimetry,
radioiodinated to deliver an estimated absorbed dose of 27 Gy to the critical
normal organ receiving the highest radiation exposure. Patients remained in
radiation isolation until the radiation exposure at 1 meter was <.07 milli-
sievert (mSv)/hour (7 millirem/hour).Table 1
Baseline Characteristics
Characteristic Value
Female 6 (17%)
Age, median (range), yr 65 (60-76)
Stage III/IV 34 (94%)
Elevated LDH 13 (36%)
>1 extranodal site 14 (39%)
Histology
Mantle cell 23 (64%)Fludarabine Infusions
Fludarabine administration began approximately 72 hours after the
therapeutic 131I-tositumomab infusion to minimize the juxtaposition of
synergizing chemotherapy with the early postinfusion period of nonspeciﬁc
blood pool and normal organ radiation exposure andmaximize overlapwith
uptake of the radioconjugate in hematolymphoid sites. Fludarabine in-
fusions were delivered to patients while in radiation isolation after pre-
medication with ondansetron per the dose escalation schema, ranging from
50 to 210 mg/m2.Diffuse large B-cell 8 (22%)
Indolent B-NHL 5 (14%)
No. prior regimens, median (range) 2 (1-9)
Prior rituximab 36 (100%)
Rituximab refractory 17 (47%)
Chemoresistant 12 (33%)
LDH indicates lactate dehydrogenase; B-NHL, B cell non-Hodgkin lym-
phoma.
Data presented are n (%) unless otherwise indicated.Hematopoietic Stem Cell Transplantation and Supportive Care
Hematopoietic stem cells were infused per standard institutional prac-
tice once the radiation exposurewas<.02 mSv/hour (2 mR/hour) at 1 meter.
Filgrastim  5 mg/kg/day was delivered starting 1 day after hematopoietic
stem cells infusion and continued until the ANC>1000/mL 2 days. A single
6 mg dose of pegﬁlgrastim was allowed as an alternative. Antibiotics, blood
products, and other supportive care measures followed institutional stan-
dard practice.Data Collection and Follow-Up
Patients were followed with computerized tomography at 1, 3, 6, and
12 months after ASCT and yearly thereafter. Bone marrow evaluations,
including cytogenetics, were performed at 1 month and then annually.
Response was scored using standard criteria [15]. Toxicity was measured on
the Bearman transplant scale as well as the National Cancer Institute
Common Toxicity Criteria scale version 3.0 [16]. Patients achieving less than
a partial response (PR) from the regimen immediately preceding this ther-
apy were categorized as having “chemoresistant” disease.
Statistical Analysis
The primary endpoint of this phase I trial was to identify the highest
ﬂudarabine dose level that would yield a dose-limiting toxicity (DLT) rate of
 25%. A DLT was deﬁned as a grade III or IV adverse event on the Bearman
transplant toxicity scale. We treated patients in cohorts of 4 and performed
dose escalation if none of the 4 dose DLTs were observed, maintained the
dose level if 1 of 4 DLTs were observed, or de-escalated if  2 of 4 DLTs were
observed. Additional patients beyond the requisite 4 were allowed on a dose
level if the prior patients had not completed sufﬁcient follow-up to be
evaluable for DLTs and they clinically required urgent transplantation.
Overall and progression-free survival were estimated using the method of
Kaplan-Meier [17].
RESULTS
Patient Characteristics
Thirty-six patientswere enrolled and treated between July
2005 and May 2011. All patients who underwent bio-
distribution infusions went on to therapeutic infusions.
Characteristics of these patients included median age of
65 years (range, 60 to 76), age 70 years for (19%), stage III or
IV for 34 (94%), median number of prior regimens of 2 (range,
1 to 9), chemoresistant disease in 12 (33%),>1 extranodal site
in 14 (39%), elevated lactate dehydrogenase at treatment in 13
(36%), and International Prognostic Index score at transplant
of 3 to 5 in 53% (Table 1). All patients had received prior
Table 4
Patients with Grades Three through Five Nonhematologic Adverse Events
within 100 Days of ASCT Regardless of Attribution
Adverse Event Grade 3 Grade 4 Grade 5
Allergy/immunology 2 (6) - -
Cardiac (general) 2 (6) - -
Constitutional symptoms 1 (3) - -
Dermatology/skin 2 (6) - -
Gastrointestinal 10 (28) - -
Table 3
Dose Escalation Schema and Dose-Limiting Toxicities of High-Dose (27 Gy) I-
131 Tositumomab and Fludarabine and ASCT
Dose
Level
n Fludarabine Daily
Dose (mg/m2)
No. of
Doses
Total Dose
(mg/m2)
No. of
DLT
0 7 10 5 50 0
1 5 15 5 75 0
2 5 20 5 100 0
3 5 25 5 125 0
4 6 30 5 150 0
5 5 30 6 180 0
6 3 30 7 210 0
DLT indicates dose-limiting toxicity.
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(deﬁned as lack of remission after or relapse within 6 months
of rituximab containing regimen). Histologic subtypes
included MCL in 23 (9 in ﬁrst complete remission), diffuse
large B cell (DLBCL) in 8 (with 5 transformed from follicular
lymphoma), follicular lymphoma in 3, marginal zone in 1, and
Waldenstrom’s in 1. The pretransplantation MCL interna-
tional prognostic index scores for the 23 MCL patients
included 10 low risk, 11 intermediate risk, and 2 high risk. All
8 of the DLBCL patients had either not achieved a complete
remission (CR) after or experienced relapsewithin 12 months
of rituximab-chemotherapy combinations, and only 4 had
chemosensitive disease going into transplantation.
Therapy Delivered
131I-tositumomab
The 131I-tositumomab protein dose for dosimetry and
therapy was 1.7 mg/kg in 3 patients and 485 mg ﬂat dose in
33. A median activity of therapeutic 131I administered was
17.4 Gbq (471 mCi; range 9.6 to 59.9 Gbq; 260 to 1620 mCi).
The critical normal organs receiving up to a 27 Gy absorbed
radiation exposurewere lungs (30), liver (4), and kidneys (2).
Details of the absorbed radiation exposures across key or-
gans and whole body based on delivered 131I activity are
described in Table 2. The median duration of radiation
isolation was 9 days (range, 5 to 15 days).
Fludarabine
Fludarabine was administered to patients while in radi-
ation isolation according to the dose escalation schema
summarized in Table 3, starting approximately 72 hours after
the therapeutic 131I-tositumomab infusion to overlap with
when lymph node retention of radioisotope typically exceeds
that of nontarget organs. Fludarabine was escalated from
10 mg/m2 daily  5 days (total dose 50 mg/m2) to 30 mg/m2
daily 7 days (total dose 210 mg/m2) without observation of
a DLT.
ASCT
The median infused CD34 cell dose was 5.42  106/kg
(range, 2.4 to 13.2  106/kg) and occurred a median of
14 days (range, 12 to 18 days) after the therapeutic 131I-
tositumomab infusion.
Estimation of the MTD, Early Toxicity, and Engraftment
There were no treatment-related deaths, no grade III or IV
toxicities on the Bearman scale, and no DLTs observed. The
MTDwas estimated to be 210mg/m2 ﬂudarabine combined
with 131I-tositumomab to deliver 27 Gy to critical normal
organs. Twenty-ﬁve patients (69%) remained outpatients forTable 2
Estimated Absorbed Radiation Doses
Organ Site Absorbed Radiation
Dose (cGy/mCi)
Absorbed Radiation
Dose (Gy)
Lungs 5.36 (1.59-10.8) 26.9 (14.6-28.1)
Liver 3.94 (1.27-5.72) 18.2 (6.5-27.9)
Kidney 3.53 (.42-6.13) 14.0 (2.96-27.5)
Spleen 6.08 (1.97-31.1) 27.8 (10.1-207)
Thyroid 4.67 (.66-23.6) 26.8 (1.88-108)
Brain .55 (.28-0.89) 2.66 (1.33-4.67)
Bone marrow .86 (.45-1.24) 4.06 (2.26-17.01)
Total body .87 (.4-1.25) 4.22 (2.6-6.54)
cGy indicates centigray.
Data presented are median (range).the duration of the post-transplantation period after
discharge from radiation isolation and did not require hos-
pitalization for toxicity. Only 2 patients developed grade 4
nonhematologic toxicities (hypokalemia/hypophosphatemia,
depression). Within the ﬁrst 100 days after transplantation,
grade 3 nonhematologic adverse events were observed in 28
patients, with the most frequent being infection (n ¼ 16;
fever without neutropenia, febrile neutropenia, clostridium
difﬁcile colitis), gastrointestinal toxicity (n ¼ 10; anorexia,
nausea, diarrhea), and laboratory/metabolic abnormalities
(n ¼ 9; electrolyte abnormalities, hypoalbuminemia, elevat-
ed transaminases). The 1 early post-transplantation death
resulted from renal failure due to ureteral obstruction from
progressive tumor. The details of key nonhematologic ad-
verse events are summarized in Table 4. There was no cor-
relation of grade of toxicity with dose level.
Expected myeloablation and grade 4 hematopoietic
toxicity were observed in all patients. The median time to
neutrophil (>500/mL) and platelet (>20 K/ml) engraftment
were 10 days (range, 8 to 18 days) and 12 days (range, 1 to
>27 days) after ASCT, respectively. Seven patients required
platelet transfusions beyond day 30.Response, Overall, and Progression-Free Survival
Post-transplantation remission status included CR/com-
plete response, unconﬁrmed in 26 (79%), PR in 2 (6%), stableGenitourinary 1 (3) - 1 (3)*
Hemorrhage 6 (17) - -
Hepatic - - -
Infection/febrile neutropenia 16 (44) - -
Lymphatics 1 (3) - -
Metabolic/laboratory 9 (24) 1 (3) -
Musculoskeletal 1 (3) - -
Neurologic 1 (3) 1 (3) -
Pain 3 (8) - -
Pulmonary 4 (11) 0 (0) -
Secondary malignancy - - -
Vascular 1 (3) - -
Any adverse event 28 (78) 2 (6) 1 (3)*
Data presented are n (%).
Adverse events graded according to the National Cancer Institute’s Common
Terminology Criteria for Adverse Events, version 3.0 scale.
* Renal failure and death due to tumor progression.
Figure 2. (A) Overall and progression-free survival at median follow-up of
3.9 years. (B) Cumulative incidence of relapse and nonrelapse mortality. (C)
Survival outcomes by Bcell lymphoma histology.
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Remission status by histology included MCL (19 [83%] CR, 1
[4%] PR), DLBCL (3 [50%] CR, 0 PR), and indolent lymphoma (3
CR/uCR [60%], 1PR [20%]). Twenty patients are currently alive
and 16 are alive and progression-free with a median follow-
up of 3.9 years. The 4 patients with evidence of pre-
transplantation minimal residual disease in the marrow (4
ﬂow þ, 1 ﬂow and PCR þ) attained a minimal residual dis-
easeenegative state by 30 days after transplantation. The
estimated 3-year overall and progression-free survival were
54% and 53%, respectively (Figure 2A). The cumulative inci-
dence of relapse and nonrelapse mortality at 3 years were
41%, and 7%, respectively (Figure 2B).
Univariate analysis indicated that increasedmortality was
observed in thosewith 2 prior regimens (hazard ratio [HR],
6.80; 95% conﬁdence interval [CI], 1.53 to 30.36; P ¼ .01) and
trend to inferior survival was noted in patients with DLBCL
(HR, 2.78; 95% CI, .96 to 8.06; P ¼ .06) (Figure 2C) and che-
moresistant disease (HR, 2.45; 95% CI, .88 to 6.81; P ¼ .09). In
contrast, there was no statistical association of inferior sur-
vival in those with more advanced age (HR, 1.05; P ¼ .45).
Delayed Effects
Three cases of acute myelogenous leukemia (AML)/mye-
lodysplastic syndrome (MDS) developed after therapy
including 1 with normal cytogenetics, mutated nucleo-
phosmin, and unmutated FLT3,1 with complex cyotogenetics
in a patient harboring cytogenetic abnormalities before
transplantation, and 1 with unknown cytogenetics. One
additional patient developed squamous cell carcinoma of the
skin. Late nonrelapse deaths also occurred in 4 patients
because of pneumonia/pnuemonitis (2), unknown causes (1),
and renal failure after an allogeneic transplantation for MDS
(1), at 5 months, 6 months, 1.1 years, and 3.7 years,
respectively.
DISCUSSION
In this manuscript, we describe the ﬁrst use of concurrent
chemoradioimmunotherapy in a myeloablative setting and
demonstrate that up 210 mg/m2 of ﬂudarabine can be safely
administered along with 131I-tositumomab to deliver 
27 Gy to critical normal organs in older adults with B-NHL.
This study builds on our prior work showing that myeloa-
blative doses of single agent 131I-tositumomab could be uti-
lized as a safe and effective approach in older adults [9]. As
not all patients were cured with the use of our prior single-
agent high-dose RIT approach and nonhematologic toxicity
was minimal, we undertook a rational strategy to further
optimize this regimen by adding ﬂudarabine, an agent we
demonstrated in preclinical models to best optimize the
antitumor effects of RIT, when compared with more tradi-
tional high-dose compounds, such as cyclophosphamide and
etoposide [10,11]. We and others have previously reported
the combinations of ﬂudarabine and radioimmunotherapy;
however, without the use of hematopoietic stem cell sup-
port, the ability to overlap these therapies has been limited
due to myelosuppression [18-20]. Furthermore, no groups
have attempted to maximize the synergistic effect by esca-
lating the total ﬂudarabine exposure beyond those used in
standard regimens.
We were able to escalate the total dose of ﬂudarabine to
210 mg/m2 without identifying a true MTD and did not
attempt to deliver additional doses, as the chemotherapy
dates would have encroached upon the day of PBSC infu-
sion. Despite the high cumulative amount of this knownlympho-depleting agent, increased rates of opportunistic
infections, such as cytomegalovirus, were not observed and
likely abrogated by the T cellereplete autologous graft. We
did observe secondary myeloid disorders, though our
sample size is not sufﬁcient to determine if the rates were
signiﬁcantly lower than observed in other studies of ﬂu-
darabine combinations and transplantation [21,22]. The 3
cases of MDS/AML after this regimen, identiﬁed by pro-
spectively collected annual bone marrow evaluations, are
similar to a much larger retrospectively collected data set in
younger patients (median age, 40 years) showing rates 8.6%
Table 5
Data from Selected Series of Lymphoma Patients Undergoing High-Dose Therapy and Autologous Transplantation
First Author/Year Age, Median
(Range), yr
n Design Conditioning 100-Day
TRM
NRM OS PFS
Gopal 2001 [2] 62 (60-68) 53 Retrospective BuMelTT (45%),
CY-TBI/CY-VP-16-TBI (45%)
9.4% 22% at 4 yr 33% at 4 yr 24% at 4 yr
Buadi 2006 [32] 66 (60-77) 93 Retrospective BEAM (60%), BEAC (40%) 5.4% NA Median 25 mo Median 13 mo
Jantunen 2006 [3] 63 (60-70) 88 Retrospective BEAC (56%), BEAM (39%) 11% 19% at 4 yr 44% at 5 yr 45% at 5 yr
Gopal 2007 [9] 64 (60-76) 24 Prospective Anti-CD20 RIT (100%) 0% 4% at 2 yr 59% at 3 yr 51% at 3 yr
Jantunen 2008 [4] 63 (60-74) 463 Registry BEAM (73%) 4.4% 10.8% at 3 yr 60% at 3 yr 51% at 3 yr
Wildes 2008 [33] 64 (60-73) 59 Retrospective BEAM (100%) 8.5% NA Median 48 mo Median 21 mo
Elstrom 2012 [34] 71 (69-86) 21 Retrospective CBV or BEAM (86%) 19% NA Median 8 mo Median 18 mo
Gopal 2014 (this study) 65 (60-76) 36 Prospective Anti-CD20-RITþ ﬂudarabine 0% 7% at 3 yr 54% at 3 yr 53% at 3 yr
TRM indicates treatment-related mortality; NRM, nonrelapse mortality; OS, overall survival; PFS, progression-free survival; Bu, busulfan; Mel, melphalan; TT,
thiotepa; CY, cyclophosphamide; TBI, total body irradiation; BEAM, carmustine, etoposide, cytarabine, melphalan; BEAC, carmustine, etoposide, cytarabine,
cyclophosphamide; Anti-CD20-RIT, I-131-tositumomab; CBV, cylcophosphamide, carmustine, etoposide.
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evidence of a malignant myeloid clone based on abnormal
bone marrow cytogenetics before transplantation and a
second with a phenotype (FLT3 negative, NPM1 positive)
not typically associated with therapy-induced AML. This
second patient achieved and has maintained a CR for over
4 years with cytarabine-idarubicin induction, followed by
high-dose cytarabine consolidation. We did, however,
observe 2 late nonrelapse deaths in patients with lung
toxicity and infection, potentially related to their radiation-
based conditioning regimen.
Efﬁcacy estimates were not a primary endpoint of this
phase I trial; thus, major conclusions should not be drawn
from these data. The best results were observed in patients
with MCL and indolent B cell lymphoma, with the majority
achieving remission durations beyond 3 years. In contrast,
only 2 of 8 of patients with DLBCL achieved progression-free
survival over 2 years in our series. These results are not
surprising because all had resistance or early relapse after
rituximab-chemo, a feature clearly associated with poor
outcome in similar but younger patients [24].
It is important to note that certain specialized expertise
and infrastructure for handling high-activity gamma emit-
ting radionuclides are required for delivering this therapy.
Patients at our center were housed for a median of 9 days in
standard lead-lined rooms (the same rooms also utilized for
131I thyroid ablation). This prolonged radiation isolation stay
clearlymay add to the cost of the transplantation; however, it
is in contrast to the median of 19.5 inpatient days required
for patients age 60 years and older undergoing BEAM (car-
mustine, etoposide, cytarabine, melphalan) conditioning for
lymphoma at our center. A recent validation study from the
European Group for Blood and Marrow Transplantation
suggests that the maximum acceptable time in the hospital
for lymphoma patients undergoing autologous trans-
plantation is 25 days, much longer than our patients expe-
rienced [25]. Our current studies focus on the therapeutic use
of isotopes, such as 90Y, which are free of appreciable gamma
emissions targeting either CD20 or CD45, further reducing
the potential economic cost and broadening the applicability
of this approach [26,27].
This study is the largest prospective autologous trans-
plantation trial designed for older patients with lymphoma
and highlights the importance of developing novel condi-
tioning regimens for adults in this age group. A recent
retrospective European Group for Blood and Marrow Trans-
plantation series suggested that, despite the majority of
DLBCL diagnoses occurring in adults over the age of 60, only
18% of autologous transplantations were performed in thisage group, and these patients suffered twice the rate of
nonrelapse mortality [4]. Similarly, in MCL, where trans-
plantation evaluated in prospective trials appears to improve
outcomes, most trials to date have limited the upper age to
60 to 65 years, relegating such individuals to less intensive
strategies [28-31]. In contrast, our series included 23 patients
withMCL; 10 were older than 65 years. To place these data in
some context, a selection of series evaluating autologous
transplantation for lymphoma in older adults is provided in
Table 5, though caution should be employed in comparing
nonrandomized series of patients with varied baseline
features.
We hypothesized that both the targeted delivery and
individualized pharmacokinetically based dosing of the
radioimmunoconjuate make it an ideal approach for older
adults who may have increased variation in organ function
for drug clearance and impaired tissue repair mechanisms.
We then built on this concept by translating preclinical data
indicating that nucleoside analogs may be a preferred agent
to concurrently combine with myeloablative radio-
immunotherapy. The results of this trial indicate that high
cumulative doses of ﬂudarabine can be safely delivered with
high-dose 131I-tositumomab and, more importantly,
strengthen the contention that arbitrary age cutoffs should
not be implemented for transplantation eligibility, particu-
larly with regimens speciﬁcally designed for an older age
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